PMID- 30042267
OWN - NLM
STAT- MEDLINE
DCOM- 20180910
LR  - 20180910
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 45
IP  - 7
DP  - 2018 Jul
TI  - [Neuromuscular Adverse Events].
PG  - 1036-1040
AB  - Neuromuscular adverse events(AEs)associated with cancer treatment with immune 
      checkpoint inhibitors(ICIs)include diverse clinical subsets. The general features 
      of neuromuscular AEs have not been elucidated because the frequency is generally 
      low, ranging from 1-2%of cancer patients undergoing ICIs therapy. The diseases 
      affect the central nervous system, peripheral nerves, neuromuscular junction, and 
      muscle. Disease onset and progression may be rapid with a critical clinical 
      course. The clinical presentation may be different from that of patients 
      unrelated to drugs. Headache, dizziness, and dysgeusia were relatively common and 
      mild treatment-related AEs. In contrast, representative immune-related AEs such 
      as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, and 
      myositis were serious. There was a tight association between myasthenia, 
      myositis, and myocarditis. There are guidelines for the treatment of 
      neuromuscular immune-mediated AEs. For all but the minimum neurological symptoms, 
      checkpoint inhibitor therapy should be withheld until the nature of the AEs is 
      defined. Immune-modulating medication is generally effective for neuromuscular 
      AEs. Both CD8+ cytotoxic T-cells and autoantibodies are involved in the 
      pathogenesis of neuromuscular AEs. Correct understanding of neuromuscular AEs is 
      required for the best management of cancer patients.
FAU - Suzuki, Shigeaki
AU  - Suzuki S
AD  - Dept. of Neurology, Keio University School of Medicine.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
SB  - IM
MH  - Humans
MH  - Molecular Targeted Therapy/*adverse effects
MH  - Neoplasms/*drug therapy/immunology
MH  - Neuromuscular Diseases/*chemically induced/therapy
MH  - Prognosis
EDAT- 2018/07/26 06:00
MHDA- 2018/09/11 06:00
CRDT- 2018/07/26 06:00
PHST- 2018/07/26 06:00 [entrez]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2018/09/11 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2018 Jul;45(7):1036-1040.